PE01407: Scottish Cancer Drug Fund

• SPICe briefing (170KB pdf)
• Further SPICe Briefing (130KB pdf)
• Written Questions for PE1407 (80KB pdf)

Summary:

15 November 2011: The Committee took evidence from Jamie Walker and James Walker and agreed to write to the Scottish Government, Breakthrough Breast Cancer, Macmillan Cancer Support, Myeloma UK, Cancer Research UK, Rarer Cancers Foundation, Scottish Medicines Consortium, Royal College of Radiologists, Procurement Scotland and the Royal Pharmaceutical Society seeking responses to points raised in the petition and during the discussion. Link to Official Report 15 November 2011 (380 KB pdf)

21 February 2012: The Committee agreed to close the petition under Rule 15.7 on the grounds that the Scottish Government has no plans to reconsider its policy on a Scottish cancer drugs fund; has sought to improve access to all newly licensed medicines; has confirmed that further guidance will be issued and will work with the Department of Health to develop and implement VBP (value-based pricing). Link to Official Report 21 February 2012 (431KB pdf)

Written Submissions:

• PE1407/A: Scottish Medicines Consortium Letter of 12 January 2012 (176KB pdf)
• PE1407/B: Macmillan Cancer Support Letter of 17 January 2012 (182KB pdf)
• PE1407/C: Myeloma UK Letter of 18 January 2012 (99KB pdf)
• PE1407/D: Breakthrough Breast Cancer Letter of 18 January 2012 (276KB pdf)
• PE1407/E: Cancer Research UK Letter of 19 January 2012 (80KB pdf)
• PE1407/F: Scottish Government Letter of 20 January 2012 (173KB pdf)
• PE1407/G: Petitioner Letter of 9 February 2012 (47KB pdf)
• PE1407/H: Roche Products Ltd Letter of 10 February 2012 (133KB pdf)
• PE1407/I: Rarer Cancers Foundation Letter of 14 February 2012 (106KB pdf)